We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Cardiac Blood Markers Can Strongly Predict Future Cancer Risk

By LabMedica International staff writers
Posted on 18 Jun 2025

Cancer and heart disease are traditionally treated as separate conditions, but new research suggests they may be more closely linked than previously believed. More...

In a major discovery, scientists have found that specific cardiac blood markers—typically used to assess heart health—can strongly predict future cancer risk, even in individuals with no symptoms or history of cardiovascular disease. This insight could pave the way for improved risk assessment tools that help detect cancer earlier in seemingly healthy people.

The findings come from a large-scale study conducted by UCLA Health (Los Angeles, CA, USA) using data from the Multi-Ethnic Study of Atherosclerosis (MESA), a long-term prospective cohort study involving 6,244 adults aged 45 to 84 years. At the time of enrollment, participants had no known cardiovascular disease or cancer. Researchers followed these individuals over a median of 17.8 years and tracked cancer occurrences using hospitalization records. The team focused on two cardiac biomarkers—high-sensitivity cardiac troponin T (hs-cTnT) and N-terminal pro–B-type natriuretic peptide (NT-proBNP)—which are often measured in cardiology to detect heart injury and stress. Blood samples collected at baseline were analyzed to assess the levels of these markers, and researchers examined their relationship with subsequent cancer diagnoses. The study, published in Journal of the American College of Cardiology: Advances, showed that even small increases in hs-cTnT and NT-proBNP levels were strong, independent predictors of overall cancer risk.

Elevated levels of both markers were particularly associated with a higher likelihood of developing colorectal cancer. Additionally, NT-proBNP alone was linked to an increased risk of lung cancer. These associations held true even after adjusting for traditional risk factors such as age and lifestyle. The practical implication of this research is significant. By incorporating cardiac biomarker testing into routine health screenings, clinicians may be able to identify individuals at heightened risk for certain cancers, even before symptoms appear. This early identification could allow for earlier interventions, closer monitoring, and potentially better outcomes for patients. Overall, this study offers a novel perspective on how heart-related diagnostics can inform cancer risk, reinforcing the potential for more integrated and preventive approaches to managing two of the world’s deadliest diseases.

“These biomarkers are already well-known indicators of cardiovascular risk, but our findings suggest their predictive power may reach well beyond heart disease to encompass cancer risk too,” said Dr. Xinjiang Cai, a UCLA Health cardiologist and physician-scientist, and lead author of the study. “The idea that slight elevations of heart-related blood markers might also help flag cancer risk in people with no known heart problems highlights how interconnected cardiovascular health and cancer may be, beyond just their shared common risk factors.”


New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Serological Pipet Controller
PIPETBOY GENIUS
New
Automatic Hematology Analyzer
LABAS F9000
New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.